MYO18B Antibody, HRP conjugated
Description
Key Uses in Experimental Workflows
-
ELISA: Primary application for quantitative detection of MYO18B in human samples .
-
Immunohistochemistry (IHC): Compatible with paraffin-embedded tissues when optimized .
-
Western Blot (WB): Detects MYO18B at ~280–290 kDa, though HRP conjugation is less common for WB compared to unconjugated variants .
Recommended Dilutions
| Application | Dilution Range | Source |
|---|---|---|
| ELISA | Manufacturer-dependent | |
| IHC (paraffin) | 1:250–1:1000 | |
| Immunofluorescence | 1:50–1:500 |
Research Findings Enabled by MYO18B Antibodies
MYO18B antibodies, including HRP-conjugated variants, have been critical in elucidating the protein’s roles in:
-
Cancer Biology: MYO18B suppresses anchorage-independent growth in lung cancer cells and is frequently downregulated in ovarian and lung cancers .
-
Muscle Disorders: Truncating mutations in MYO18B are linked to severe nemaline myopathy and cardiomyopathy, as shown by absent full-length protein in Western blots .
-
Cellular Mechanisms: MYO18B facilitates lysosomal exocytosis near focal adhesions, a process requiring actin crosslinking and Ca²⁺ signaling via PIEZO1 channels .
Comparative Analysis of MYO18B Antibodies
Product Specs
Target Background
MYO18B Function and Clinical Relevance:
- Complete loss of MYO18B function leads to a complete absence of sarcomeric structure, highlighting its crucial role in sarcomere assembly. Interestingly, disorganized thin and thick filaments are observed throughout the sarcoplasm, suggesting a novel model where MYO18B coordinates the integration of pre-formed filaments into the sarcomere. PMID: 28104788
- MYO18B deficiency is associated with a novel developmental disorder characterized by a combination of Kabuki syndrome features (KFA) and myopathy. PMID: 25748484
- No association was found between rs133885 in MYO18B and mathematical abilities in individuals with dyslexia or the general population. PMID: 25778778
- A common MYO18B variant is linked to mathematical disability in children with dyslexia and intraparietal sulcus variability in neurotypical adults. PMID: 23423138
- MYO18B is identified as a candidate tumor suppressor gene on chromosome 22q12.1, frequently deleted, mutated, or methylated in human lung cancer. PMID: 12209013
- Human MYO18B, a novel unconventional myosin heavy chain expressed in striated muscles, translocates to the myonuclei during differentiation. PMID: 12547197
- MYO18B alterations, encompassing both epigenetic and genetic changes, play a significant role in ovarian carcinogenesis. PMID: 15305387
- Proteasome dysfunction, induced by a proteasome inhibitor or siRNA-mediated Sug1 knockdown, leads to MYO18B protein upregulation, indicating that MYO18B undergoes polyubiquitination in vivo. PMID: 16499872
- Restoration of MYO18B expression may offer a promising therapeutic strategy for treating locally advanced malignant pleural mesothelioma (MPM). PMID: 17294804
Q&A
Basic Research Questions
-
What is MYO18B and what are its known cellular functions?
MYO18B (Myosin-18B) is an unconventional myosin heavy chain primarily expressed in cardiac and skeletal muscles . It plays significant roles in cytoskeletal organization, particularly in the assembly of myosin II stacks and stress fiber formation. Research demonstrates that MYO18B localizes to contractile ventral stress fibers and a subset of transverse arcs, while being absent from non-contractile dorsal stress fibers . At the molecular level, MYO18B is associated with the ATPase proteasome subunit Sug1 and serves as a substrate for proteasomal degradation . Additionally, it may be involved in intracellular trafficking when in the cytoplasm and regulation of muscle-specific genes when in the nucleus .
-
What applications are HRP-conjugated MYO18B antibodies validated for?
Based on available data, HRP-conjugated MYO18B antibodies are suitable for multiple research applications:
Application Recommended Dilution Notes Western Blotting (WB) 1:300-5000 Detects MYO18B protein expression in lysates Flow Cytometry (FCM) 1:20-100 Analyzes MYO18B at cellular level Immunohistochemistry (IHC-P) 1:200-400 Visualizes MYO18B in tissue sections The HRP conjugation eliminates the need for secondary antibody incubation, potentially reducing background and simplifying protocols .
-
How should researchers validate MYO18B antibody specificity?
Validation is particularly important as studies indicate that many MYO18B antibodies recognize additional proteins. Recommended validation approaches include:
-
Comparing staining patterns between wild-type and MYO18B knockout cells, as demonstrated in published research
-
Testing antibody recognition of overexpressed MYO18B-GFP fusion proteins
-
Performing Sanger sequencing analysis of knockout cell lines to confirm gene disruption
-
Conducting Western blot analysis with appropriate positive and negative controls
-
Using immunofluorescence microscopy to confirm specific subcellular localization patterns
One study found that while some MYO18B antibodies showed nonspecific bands on Western blots, they displayed specific stress fiber staining in immunofluorescence that was absent in knockout cells .
-
-
What parameters should be considered when selecting storage and handling conditions for MYO18B antibodies?
Optimal storage and handling are critical for maintaining antibody functionality:
-
Storage temperature: Store at -20°C for maximum shelf life (typically 12 months)
-
Buffer composition: Commonly supplied in TBS (pH 7.4) with BSA, preservatives like Proclin300, and glycerol
-
Avoid repeated freeze-thaw cycles which may compromise antibody activity
-
Working dilutions should be prepared fresh and used within recommended time frames
-
When using HRP-conjugated antibodies, protect from prolonged light exposure
-
Always centrifuge antibody vials briefly before opening to collect solution at the bottom
-
